Aura Biosciences Q1 net loss widens to $33.7 million; $280.8 million raised in offering
Aura Biosciences reported first quarter 2026 results, with a net loss of $33.7 million, up from $27.5 million a year earlier. The loss per share narrowed to $0.50 from $0.55, and the company said a $280.8 million net-proceeds stock offering completed May 5, 2026, should fund operations into the second half of 2028.
Key points
- Net loss was $33.7 million for the quarter ended March 31, 2026, versus $27.5 million a year earlier; basic and diluted loss per share was $0.50 versus $0.55.
- Research and development expenses rose to $28.0 million from $23.3 million, mainly due to the Phase 3 CoMpass trial in early choroidal melanoma.
- Cash, cash equivalents and marketable securities were $114.7 million at March 31, 2026, before the offering; about $39.0 million of offering proceeds was used to repurchase shares held by Matrix Capital Management Master Fund, LP.
- Natalie Holles became Chief Executive Officer and President effective April 30, 2026, succeeding founder Elisabet de los Pinos, Ph.D.
The filing
Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 11, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.